Goldman Sachs
Communacopia +Technology Conference

September 10, 2024

Safe harbor statement
The information provided in this presentation contains forward-looking statements within the meaning of the federal securities laws. These
forward-looking statements may include, among others, statements regarding operating results, the success of our internal operating plans,
and the prospects for newly acquired businesses to be integrated and contribute to future growth, profit and cash flow expectations.
Forward-looking statements may be indicated by words or phrases such as "anticipate," "estimate," "plans," "expects," "projects," "should,""will," "believes," "intends" and similar words and phrases. These statements reflect management's current beliefs and are not guarantees offuture performance. They involve risks and uncertainties that could cause actual results to differ materially from those contained in any
forward-looking statement. Such risks and uncertainties include our ability to identify and complete acquisitions consistent with our businessstrategies, integrate acquisitions that have been completed, realize expected benefits and synergies from, and manage other risks associatedwith, acquired businesses, including obtaining any required regulatory approvals with respect thereto. We also face other general risks,
including our ability to realize cost savings from our operating initiatives, general economic conditions and the conditions of the specificmarkets in which we operate, including risks related to labor shortages and rising interest rates, changes in foreign exchange rates,difficulties associated with exports, risks associated with our international operations, cybersecurity and data privacy risks, including litigation
resulting therefrom, risks related to political instability, armed hostilities, incidents of terrorism, public health crises (such as the COVID-19
pandemic) or natural disasters, increased product liability and insurance costs, increased warranty exposure, future competition, changes inthe supply of, or price for, parts and components, including as a result of the current inflationary environment and ongoing supply chain
constraints, environmental compliance costs and liabilities, risks and cost associated with litigation, potential write-offs of our substantial
intangible assets, and risks associated with obtaining governmental approvals and maintaining regulatory compliance for new and existingproducts. Important risks may be discussed in current and subsequent filings with the SEC. You should not place undue reliance on any
forward-looking statements. These statements speak only as of the date they are made, and we undertake no obligation to update publicly
any of them in light of new information or future events.

We refer to certain non-GAAP financial measures in this presentation. Reconciliations of these non-GAAP financial measures to the mostdirectly comparable GAAP financial measures can be found within this presentation.
2

We compound cash flowby acquiring and growing
niche, market-leading
technology businesses.

3

By the numbers
Revenue growth

Revenue growth + FCF margin

Doubledigit

Ruleof 40+Margins​

Business mix

Recurring & reoccurring

70%+ Gross margin
40%+ EBITDA margin
30%+ FCF margin~75%

Vertical software

~85%

~25%

Medical & waterproducts

70%+ Of total

2024E Revenue~$7B

Of verticalsoftware4Roper’s 2023 revenue composition
$6.2B

$4.6B

$1.6B

$0.2B Perpetual licenses

100%
90%
80%

$3.5B
$0.9B

Medical & waterproducts$0.5B Services and other$0.4B Reoccurring

On-prem annual
maintenance

$4.6B

$3.5B

$2.6B

70%
60%
50%
40%

Vertical software

Recurring

SaaS subscription

Total revenue

Vertical software revenue

Recurring software revenue

30%
20%
10%
0%

2023 revenue from continuing operations. Numbers may not foot due to rounding.

5Market-leading businesses
in defensible niches

Process-driven
capital deployment

Decentralized
operatingenvironment

6

Long-term compounding growth algorithm
Market-leading businesses
in defensible niches

Double-digit revenue growth
MSD+ organic growth
Patient & disciplined capital deployment+45%+ operating leverageHigh margin niche leaders
Improve what we own=Mid-teens free cash flow
compounding
Processdriven capital
deployment

Decentralized
operatingenvironment

High cash return business models
Long runway ahead

7

Cumulative total shareholder return
ROPER TECH

+2,392%Long-term
outperformance
Business model & strategy designed forlong-term value creation

S&P 500+536%

8Appendix

Double-digit revenue growth profile
Organic revenue growth

Total revenue growth20%

Pandemic year

15%

13%

~12%

11%

11%
9%

8%

8%

6%~6%
3%

EBITDA margin

2019

2020

2021

2022

2023

2024E

38%

39%

40%

40%

41%

~41%

Results are presented on an Adjusted (Non-GAAP) and continuing operations basis.

10

Roper’s portfolio
Annual revenueBusiness$500M+$250M to $500M$100M to $250M

Less than $100M

11

Reconciliations
Adjusted revenue and EBITDA reconciliation ($M)(from continuing operations)
GAAP revenue
Purchase accounting adjustment to acquired deferred
Adjusted revenue

FY 2019*
$
3,558
11$
3,568

FY 2020
$
4,022
12$
4,034

FY 2021
$
4,834
1$
4,835

FY 2022
$
5,372
$
5,372

FY 2023
$
6,178
$
6,178

6%
6%(1%)
11%

3%
10%
13%

8%
11%
1%
20%

9%
3%(1%)
11%

8%
7%

Organic
Acquisitions / divestitures
Foreign exchange
Total adjusted revenue growth
GAAP earnings before income taxes
Interest expense
Depreciation
Amortization
EBITDA

$

$

778
186
37349
1,350

$

$

861
219
41
451
1,572

$

$

1,032
234
44572
1,882

$

$

1,282
192
37613
2,124

15%
$

$

1,743
165
35
720
2,663

Purchase accounting adjustment to acquired deferred
revenue and commission expense

1010(5)

(5)

-----

9

69-

58

1,366

1,590

94(28)
1,944

45
2,170(165)
(3)
2,511

Restructuring-related expenses associated with theSyntellis acquisition
Transaction-related expenses for completed acquisitions
and divestitures
Financial impacts associated with the minority investments
in Indicor & Certinia
Gain on sale of non-operating assets
Legal settlement charge
Impairment related to merger of Clinisys and Sunquest
Gain on sale of divested businesses
Adjusted EBITDA% of adjusted revenue$38.3%

$

39.4%

$

40.2%

$

40.4%

$

40.6%

*Excludes the results of the divestitures completed in 2019 for (i) the Scientific Imaging businesses, sold to Teledyne on February 5, 2019 and (ii) Gatan, sold to AMETEK on October 29, 2019.

12